

Clinical Priorities Advisory Group

Agenda

Monday 04 November 2019

10.30 – 17.00hrs

Monday 4th November: City Hall, The Queens Walk, London, SE1 2AA

Part I	
Agenda item no.	1. Routine Business
1.1	Welcome and introductions Sir Nick Partridge, Chair
1.2	Apologies Sir Nick Partridge, Chair
1.3	Declarations of Interest for agenda items Sir Nick Partridge, Chair
1.4	Minutes from the previous meeting held on Wednesday 2nd October Sir Nick Partridge, Chair
1.5	Public consultations – clinical policies and service specifications Sir Nick Partridge, Chair
1.6	Clinical commissioning publications agreed outside of CPAG Sir Nick Partridge, Chair
1.7	Matters Arising Sir Nick Partridge, Chair
3. Relative Prioritisation: Clinical Commissioning Policies	
Blood and Infection Programme of Care	
3.1	1709: Vonicog alfa for the treatment and prevention of bleeding in people with von Willebrand disease Mr James Palmer, Medical Director Specialised Services and Janette Harper, Senior Manager –Blood & Infection Programmes of Care
3.2	1716: Use of plasma derived Factor X concentrate to treat individuals with Factor X deficiency Mr James Palmer, Medical Director Specialised Services and Janette Harper, Senior Manager –Blood & Infection Programmes of Care
3.3	1813: Canakinumab for periodic fever syndromes Dianne Addei, Public Health Advisor and Janette Harper, Senior Manager – Blood & Infection Programmes of Care

	4. Internal Medicine Programme of Care
4.1	1622: Lung volume reduction by surgery or endobronchial valve for severe emphysema in adults Mr James Palmer, Medical Director Specialised Services and Ursula Peuple, Senior Manager – Internal Medicine Programme of Care
4.2	1832: Mercaptamine hydrochloride for corneal cystine crystal deposits caused by cystinosis Dianne Addei, Public Health Advisor and Ursula Peuple, Senior Manager – Internal Medicine Programme of Care
	5. Cancer Programme of Care
5.1	1691: Temozolomide for patients with grade 3 anaplastic astrocytoma of the brain (all ages) Dianne Addei, Public Health Advisor and Rupinder Dev, Senior Manager – Cancer Programme of Care
5.2	1825: Dexrazoxane for the prevention of anthracycline induced cardiomyopathy in children and young people receiving anthracyclines for the treatment of cancer Dianne Addei, Public Health Advisor and Rupinder Dev, Senior Manager – Cancer Programme of Care
5.3	1908: Stereotactic Ablative Body Radiotherapy (SABR) for Patients with metachronous extracranial oligometastases Mr James Palmer, Medical Director Specialised Services and Rupinder Dev, Senior Manager – Cancer Programme of Care
5.4	1913: Stereotactic Ablative Body Radiotherapy for Hepatocellular Carcinoma Mr James Palmer, Medical Director Specialised Services and Rupinder Dev, Senior Manager – Cancer Programme of Care
5.5	Open meeting close Understanding the process - questions from the audience